Multidisciplinary management of locally advanced rectal cancer
A 62-year-old man is diagnosed with rectal cancer 8 cm from the anal verge, staged as T3N1M0 by MRI and CT. He has a history of type 2 diabetes and hypertension, well controlled. His performance status is ECOG 1. The tumor board discusses neoadjuvant therapy options. The patient is concerned about the possibility of a permanent colostomy and wants to know about sphincter-preserving surgery. He also asks about the role of radiation therapy and whether he can continue working during treatment.
1. What are the key considerations in recommending neoadjuvant therapy for this patient?
Read the worked answer
For locally advanced rectal cancer (T3 or N+), neoadjuvant therapy is standard to reduce local recurrence and potentially downstage the tumor to facilitate sphincter-preserving surgery. Options include neoadjuvant chemoradiotherapy (CRT) or total neoadjuvant therapy (TNT) with chemotherapy before and/or after CRT. The choice depends on tumor characteristics, patient fitness, and goals. This patient is fit (ECOG 1) and has a mid-rectal tumor, so sphincter preservation may be feasible. TNT may increase the chance of downstaging and complete response, but it is more intensive. The multidisciplinary team should consider his diabetes (which may affect wound healing and radiation tolerance) and his work obligations. Shared decision-making should include discussion of risks (e.g., radiation proctitis, fecal incontinence, sexual dysfunction) and benefits.
2. How would you counsel the patient about the likelihood of sphincter preservation and the impact of treatment on his work?
Read the worked answer
Explain that the tumor is 8 cm from the anal verge, which is in the mid-rectum, and sphincter-preserving surgery (low anterior resection) is often possible, especially if the tumor shrinks with neoadjuvant therapy. However, a permanent colostomy may be needed if the tumor is very close to the sphincter or if there is poor response. The risk of temporary ileostomy is common but usually reversible. Regarding work, neoadjuvant chemoradiotherapy typically lasts about 5-6 weeks with daily radiation and concurrent chemotherapy, which can cause fatigue, diarrhea, and skin irritation, making full-time work difficult. TNT may require additional chemotherapy cycles. Discuss potential for flexible work arrangements or medical leave. Emphasize that the goal is curative and that the team will support him through treatment.